Investment bank Leerink Swann anticipates a four-percent decline in Illumina's core microarray business this year due to increased adoption of next-generation sequencing, a reduction in available federal funding, and competition from Affymetrix.

In a research note released last week, analyst Dan Leonard commented on the results of the bank's annual survey on microarray trends, highlighting its "cautious array forecast" as sequencing "grabs a bigger market share."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.